The primary purpose of this study is to assess the efficacy in treating patients with Major Depressive Disorder of one or more doses of Lu AA24530 relative to placebo
According to the World Health Organisation, Major Depressive Disorder is the leading cause of disability and the 4th leading contributor to the global burden of disease. There are unmet medical needs in the treatment of depressive disorders in terms of insufficient effectiveness and unpleasant side-effects of current therapies. The overall prognosis of the disorder is positive for the majority of patients, but as many as 30% of patients will develop a chronic and treatment-resistant depression. In the study, patients with depression are treated for 6 weeks. Assessments of efficacy and safety are taking place every week for the first 4 weeks and again after 6 weeks of treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
652
per oral, once daily for 6 weeks
per oral, once daily for 6 weeks
per oral, once daily for 6 weeks
The difference in change from baseline to end of treatment on the Montgomery-Åsberg Depression Rating Scale total score
Time frame: 6 weeks
Response rate, remission rate, and safety
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
AU002
Brisbane, Australia
AU001
Brisbane, Australia
AU003
Dandenc, Australia
AU004
Epping, Australia
AU006
Malvern, Australia
AT001
Vienna, Austria
AT002
Vienna, Austria
AT003
Vienna, Austria
BE003
Diest, Belgium
BE002
Sint-Niklaas, Belgium
...and 62 more locations